This article is more than 5 years old. Information may no longer be current.

VIDEO: Talazoparib improves PFS in patients with BRCA mutations

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

CHICAGO — At the ASCO Annual Meeting, Jose Pablo Leone, MD, medical oncologist at Dana-Farber Cancer Institute, spoke with HemOnc Today about the findings of the phase 3 EMBRACA trial.

The study demonstrated that patients with HER2-negative, BRCA1 or BRCA2 germline mutated, locally advanced or metastatic breast cancer treated with talazoparib (Talzenna, Pfizer) had better PFS than those treated with the physician’s choice of therapy, according to Leone, and confirm previous data.

“This data provides reassurance to many clinicians and patients in the United States who are considering this treatment option,” he said. “It also provides an insight into a new therapy for patients with germline mutations in BRCA1 or BRCA2, specifically with the use of PARP inhibitors, which is the class of action of this drug, talazoparib, and builds upon the prior knowledge of other drugs in this space as well.” – by Alaina Tedesco

Reference:

Diab S, et al. Abstract 1044. Presented at: ASCO Annual Meeting; May 31-June 4, 2019; Chicago.

Disclosure: Leone reports receiving research funding from Eli Lilly and Company and Kazia Therapeutics